Institut Pasteur

Aventis Pharma S.a.

Philippe Moullier

Olivier Danos

Jean-Michel Heard

Nicolas Ferry

Michel Perricaudet

William Vainchenker

Yves Beuzard

Nadia Naffakh

Vincent Descamps

The present invention provides cell compositions for in vivo implantation, and designed for the sustained and controlled delivery of therapeutic substances.

Composition for the in vivo production of therapeutic products

The invention relates to an implant obtained by assembling in vitro various elements in order to form a neo-organ which is introduced preferably in the peritoneal cavity of the recipient. The implant comprises a biocompatible support intended to the biological anchoring of cells; cells having the capacity of expressing and secreting naturally or after recombination a predetermined compound, for example a compound having a therapeutical interest; and a constituent capable of inducing and/or promoting the geling of said cells. The invention also relates to a kit for the preparation of the implant as well as to a new recombinant retroviral vector comprising a provirus DNA sequence modified in that the genes gag, pol and env have been deleted at least partially so as to obtain a proviral DNA capable of replication. The invention also relates to recombinant cells comprising the new retroviral vector.

Recombinant retroviral vector

Biocompatible implant for the expression and in vivo secretion of a

Growing community of inventors

Meudon, France

Philippe Moullier